Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER

https://doi.org/10.20996/1819-6446-2014-10-6-625-630

Full Text:

Abstract

Aim. To study in the PROFILE register the rate of new oral anticoagulants (NOAC) taking in patients with atrial fibrillation (AF) and to identify the factors influencing it.

Material and methods. Patients with AF who applied to the Cardiology Center in 2013-2014 (n=111) were included into the study. The oral anticoagulants (OAC) were recommended to patients at the reference visit (n=97). Inquiry in questionnaire format was performed to assess the compliance to recommended therapy at the follow-up visit. Patients were divided into two groups according to taking/not-taking NOAC. Analysis of the facts that influence the compliance to NOAC therapy was performed.

Results. At the reference visit 70 patients desired to receive NOAC. At the follow-up visit 29 (41.4%) patients refused to take NOAC. Leading causes of NOAC refusal were satisfactory with warfarin (32.6%), the high price of these drugs (23.9%), the description of adverse reactions in the patient information leaflet for medicines (15.2%), and withdrawal by physician in outpatient clinic/hospital (8.7%). Preferential provision of medicines and warfarin therapy at the time of reference visit had a negative impact on the taking of NOAC. Patients taking NOAC were more aware of the possible outcomes of their illness, the possible side effects of OAC and were more familiar with patient information leaflet for medicines.

Conclusion. The study assessed NOAC taking rate and the factors influencing patients' compliance to NOAC therapy.

About the Authors

S. Y. Martsevich
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


A. R. Navasardyan
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


N. P. Kutishenko
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


A. V. Zakharova
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


V. P. Voronina
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


N. A. Dmitrieva
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


L. Yu. Lrozdova
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


A. V. Zagrebelnyy
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


O. V. Lerman
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


Yu. V. Lukina
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


G. V. Martynova
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


A. A. Nikulina
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


G. S. Ryazanova
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


A. Yu. Suvorov
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


S. N. Tolpygina
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


References

1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001;22:1852-923.

2. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.

3. Connolly S.J., Laupacis A., Gent M., et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-55.

4. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States. J Manag Care Pharm 2009;15(3):244-52.

5. Sirotkina O.V., Ulitina A.S., Taraskina A.E. Allelic variants of the CYP2C9*2 and CYP2C9*3 gene cytochrome CYP2C9 in the population of St. Petersburg and their clinical significance in anticoagulation therapy with warfarin. Rossiyskiy Kardiologicheskiy Zhurnal 2004;(6):24–31. Russian (Сироткина О.В., Улитина А.С., Тараскина А.Е. и др. Аллельные варианты CYP2C9*2 и CYP2C9*3 гена цитохрома CYP2C9 в популяции Санкт-Петербурга и их клиническое значение при антикоагулянтной терапии варфарином. Российский Кардиологический Журнал 2004;(6): 24-31).

6. Loukianov M.M., Boytsov S.A., Yakushin S.S. et al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of «atrial fibrillation» in real outpatient practice (According to data of registry of cardiovascular diseases, RECVASA). Ration Pharmacother Cardiol 2014;10(4):366-77. Russian (Лукьянов М.М., Бойцов С.А., Якушин C.С. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным РЕгистра КардиоВАскулярных ЗАболеваний РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии 2014;10(4):366-77).

7. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-term Anticoagulant therapy (RE-LY) Trial. Circulation 2011; 123: 2363-72.

8. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-91.

9. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806-17.

10. Heidbuchel H., Verhamme P., Alingsetal M., et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants inpatients with non-valvular atrial fibrillation. Europace 2013; 15: 625-51.

11. Martsevich SYu, Gaysenok OV, Tripkosh SG. Medical supervision in specialized center and the quality of lipid-lowering therapy in patients with cardiovascular diseases (according to the PROFIL register). Ration Pharmacother Cardiol 2013;9(2):133-7. Russian (Марцевич С.Ю., Гайсёнок О.В., Трипкош С.Г. Наблюдение в специализированном медицинском центре и качество гиполипидемической терапии у пациентов с сердечно-сосудистыми заболеваниями (по данным регистра ПРОФИЛЬ. Рациональная Фармакотерапия в Кардиологии 2013;9(2):133-7).

12. MartsevichSYu, Kutishenko N.P Gaysenok OV, Tripkosh S.G. Original Medicines and Generics: an Analysis of Efficacy and Safety via Controlled Studies and Using the Register on the Example of AmlodipineKardiologiya2013; 5:83-6. Russian (Марцевич С.Ю., Кутишенко Н.П., Гайсенок О.В., Трипкош С.Г. Оригинальные препараты и дженерики: анализ эффективности и безопасности с помощью контролируемых исследований и с использованием регистра на примере амлодипина. Кардиология 2013;5:83-6).

13. Martsevich SYu, Navasardian AR, Kutishenko NP, et al. Studying atrial fibrillation on the basis of the «PROFILE» registry. Kardiovaskulyarnaya Terapiya i Profilaktika 2014; 13(2): 35-39 Russian (Марцевич С.Ю., Навасардян А.Р., Кутишенко Н.П. и др. Опыт изучения фибрилляции предсердий на базе регистра ПРОФИЛЬ. Кардиоваскулярная Терапия и Профилактика 2014; 13(2): 35-9).

14. Camm AG, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-47.

15. National guidelines for diagnosis and treatment of atrial fibrillation (2012). Available at: http://scardio.ru/content/Guidelines/FP_rkj_13.pdf. Accessed by 18.12.2014. Russian (Национальные рекомендации по диагностике и лечению фибрилляции предсердий (2012). Доступно на: http://scardio.ru/content/Guidelines/FP_rkj_13.pdf. Проверено 18.12.2014.

16. Martsevich S.Yu., Gaisenok O.V., Tripkosh S.G. et al. Real practice of statins use and its dependence on follow-up in the specialized medical centre in patients with high cardiovascular risk (according to the PROFILE register) Ration Pharmacother Cardiol 2013;9(4):362-7. Russian (Марцевич С.Ю., Гайсенок О.В., Трипкош С.Г. идр. Реальная практика назначения статинов и ее зависимость от наблюдения в специализированном медицинском центре у больных с высоким риском сердечно-сосудистых осложнений (по данным регистра ПРОФИЛЬ). Рациональная Фармакотерапия в Кардиологии 2013;9(4):362-7).


For citation:


Martsevich S.Y., Navasardyan A.R., Kutishenko N.P., Zakharova A.V., Voronina V.P., Dmitrieva N.A., Lrozdova L.Y., Zagrebelnyy A.V., Lerman O.V., Lukina Y.V., Martynova G.V., Nikulina A.A., Ryazanova G.S., Suvorov A.Y., Tolpygina S.N. THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER. Rational Pharmacotherapy in Cardiology. 2014;10(6):625-630. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-6-625-630

Views: 415


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)